Palvella Therapeutics Inc

Pal vella Therapeutics insider buying signals executive confidence in the QTORIN platform, Phase 3 data, and upcoming regulatory approvals—insightful for investors tracking market access and competitive advantage.

Insider trades at Palvella Therapeutics show routine portfolio moves, not a shift, but the COO’s deep‑discount purchases hint at long‑term conviction amid volatile biotech earnings.